BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

468.04M

Vuru Grade

23.50/100

Current Price

$5.82
-0.26 (-4.28%)

Company Metrics

  • P/E 0
  • P/S 15.79
  • P/B 12.69
  • EPS -0.63
  • Cash ROIC -144.97%
  • Cash Ratio 1.01
  • Dividend 0 / N/A %
  • Avg. Vol. 1.70M
  • Shares 80.42M
  • Market Cap. 468.04M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

BioCryst: Frustration Then Joy In Biotech Investing
Seeking Alpha - May 31, 2017
BioCryst Pharmaceuticals (NASDAQ:BCRX) has had a frustrating few months, with a progressive decline in share price since mid-March of this year (after $48 million net proceeds of equity raising).
Research focused on the hereditary angioedema market estimated to flourish by ... - WhaTech
Analyst's Bullish on these two stock Following meeting with Industry: BioCryst ...
StockNewsJournal - 14 hours ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) market capitalization at present is $476.92M at the rate of $6.08 a share.
BioCryst Pharmaceuticals, Inc. (BCRX) Lowered to “Sell” at Zacks Investment ...
BNB Daily (blog) - 13 hours ago
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections.
Investors Are Circling BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), What Do ... - Stock Talker
Investor Toolkit: ERP5 update on BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX) - Concord Register
Option Market Alert: BioCryst Pharmaceuticals Inc Implied Price Swing Hits An ...
CML News - Jun 23, 2017
Risk Alert: Before we dive into any analysis we simply note that BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) risk is elevated.
Stock Volatility Risk Alert: BioCryst Pharmaceuticals Inc Stock Volatility ...
CML News - Jun 19, 2017
Before we dive into any analysis we simply note that BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has seen its stock price whip around at an exceptional high level.
BioCryst Pharmaceuticals, Inc. (BCRX) Reaches $5.73 After 7.00% Up Move, 2 ... - UtahHerald.com
Today Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Reported Decrease in ... - Weekly Register
Today Analysts Focus on BioCryst Pharmaceuticals, Inc. (BCRX), Smart & Final ...
StockNewsJournal - Jun 19, 2017
BioCryst Pharmaceuticals, Inc. (BCRX) have shown a high EPS growth of 9.90% in the last 5 years and has earnings decline of -26.80% yoy.
Analyst's Bullish on these two stock Following meeting with Industry: BioCryst ...
StockNewsJournal - Jun 22, 2017
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) market capitalization at present is $475.97M at the rate of $5.94 a share.
Is It Time to go for BioCryst Pharmaceuticals, Inc. (BCRX), BGC Partners, Inc ...
StockNewsJournal - Jun 21, 2017
BioCryst Pharmaceuticals, Inc. (BCRX) have shown a high EPS growth of 9.90% in the last 5 years and has earnings decline of -26.80% yoy.
Analyst's Predictions on BioCryst Pharmaceuticals, Inc. (BCRX), RSP Permian ...
StockNewsJournal - Jun 1, 2017
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.
Down 24.6%, is BioCryst Pharmaceuticals Stock Now a Buy?
Motley Fool - Jun 6, 2017
Shares of the rare disease drugmaker BioCryst Pharmaceuticals (NASDAQ:BCRX) took investors on quite the ride last month.
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Rating Upgraded by Zacks ... - The Cerbat Gem
Morning Buzz: BioCryst Pharmaceuticals, Inc. (BCRX) - StandardOracle
Growth Rate Assumed by Market

We did a reverse valuation to calculate the growth rate the market is assuming for BCRX to be considered fairly valued at its current market price. It's useful to compare this to the growth rate we're assuming for the Growth Price.

Future Free Cash Flow Growth Rate

This is the annual growth rate we've applied to calculate BCRX's Free Cash Flow for the next 10 years. To calculate it, we looked at several time periods of the last 10 years. Feel free to adjust it, but we limit the initial growth rate to 20% and slow it down over the years. Otherwise, long-term sustainability issues come into play.

Discount Rate

The discount rate is the annual rate of return an investor requires to take the risk of investing in a single stock. To account for that risk, this should be above 8-10%, as this is the avg. annual rate of return for the S&P500 over the past 100 years.

$5.82 Current Price

$-4.68 Growth Price (DCF)

Why is this negative?


Show Free Cash Flow numbers

$-1.72 Book Price

Overvalued by 129.55%


Very Poor Cash Return on Invested Capital over the past 5 years

BCRX has failed to generate positive returns on its investments in buildings, projects and equipment. This could be due to poor management, lack of an economic moat or the capital intensive nature of the business.

BCRX has lost $144.97 of cash for every $100 invested.
Figures in USD. Fiscal year ends in December
20122013201420152016
Free Cash Flow -37.51M -26.56M -38.66M -18.24M -58.72M
divided by
Invested Capital 4.62M -4.45M 6.42M 8.54M -19.16M
Cash ROIC -812.61% 597.53% -602.60% -213.58% 306.40%

Very Poor Return on Equity over the past 5 years

BCRX has shown an inability to deliver results for shareholders. This could be due to poor management, BCRX operating in a highly competitive industry, or having a weak business in general.

BCRX has generated a $728.89 loss for every $100 of Shareholders' Equity.
Figures in USD. Fiscal year ends in December
20122013201420152016
Net Income -39.08M -30.11M -45.19M -43.02M -55.14M
divided by
Stockholders' Equity -454,000.00 -1.13M 75.64M 47.72M 1.58M
Return on Equity - - -59.75% -90.14% -3,494.55%

Poor Business Performance over the past 10 years

BCRX's inability to produce positive free cash flow for the majority of the past 10 years is concerning. It should be a red flag, since this company does not have a track record of delivering results for shareholders. This could be due to poor management or the nature of its business.

BCRX has been losing money for the majority of the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Free Cash Flow -25.00M -22.09M -16.82M -28.88M -32.31M -37.51M -26.56M -38.66M -18.24M -58.72M

Weak Balance Sheet

BCRX's financial position is not ideal. The key is to check whether BCRX is using debt to fuel its growth and the sustainability of that tendency. Highly capital intensive businesses (see Economic Moat) follow this route, which can deeply impact the future prospects of the business.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Cash 50.70M 61.53M 68.96M 53.95M 41.72M 35.60M 38.06M 72.77M 51.56M 54.65M
Current Assets 91.70M 75.02M 111.02M 87.42M 52.86M 41.98M 42.12M 89.34M 65.99M 66.99M
Total Assets 142.72M 84.69M 142.19M 109.45M 82.21M 57.44M 48.87M 136.87M 124.56M 89.85M
Current Liabilities 28.12M 17.11M 37.25M 27.82M 26.30M 17.22M 15.26M 57.69M 64.45M 54.36M
Total Liabilities 77.81M 38.27M 55.92M 43.94M 67.40M 57.89M 49.99M 61.24M 76.83M 88.27M
Stockholder' Equity 64.91M 46.43M 86.27M 65.50M 14.81M -454,000.00 -1.13M 75.64M 47.72M 1.58M
Current Ratio 3.26 4.39 2.98 3.14 2.01 2.44 2.76 1.55 1.02 1.23
TL-to-TA 0.55 0.45 0.39 0.40 0.82 1.01 1.02 0.45 0.62 0.98

Low or No Reinvestment of Profits over the past 10 years

BCRX has either been retaining a small amount of their earnings or has done so inconsistently. A lack of consistency could be due to BCRX operating at a loss or them having such a strong economic moat they feel comfortable spending profits on growth. Be wary of future prospects and if applicable, inspect the moat's sustainability.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Retained Earnings -224.54M -249.27M -262.72M -296.57M -353.52M -392.60M -422.71M -467.90M -510.92M -566.06M
Retained Earnings Growth - -11.01% -5.40% -12.89% -19.20% -11.05% -7.67% -10.69% -9.19% -10.79%

Erratic Net Profit Margins over the past 10 years

BCRX has had highly erratic net profit margins which are a great cause for concern. This company may operate in a highly volatile industry, or it may just have poor performance. Look at reasons for this inconsistency to understand if there is any reason to look past it.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Net Income -29.06M -24.73M -13.45M -33.85M -56.95M -39.08M -30.11M -45.19M -43.02M -55.14M
divided by
Revenue 71.24M 56.56M 74.59M 62.38M 19.64M 26.29M 17.33M 13.61M 48.26M 26.35M
Net Profit Margin -40.79% -43.73% -18.03% -54.27% -289.91% -148.64% -173.72% -332.08% -89.15% -209.25%

Strong Pricing Power over the past 10 years

BCRX has maintained substantial gross margins, suggesting that they have been able to set prices without consideration of the cost of goods sold. This potentially leaves flexibility in inflationary environments to raise prices on consumers and maintain profitability.

$97.76 of every $100 worth of sales have been Gross Profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Gross Profit 71.24M 56.56M 70.05M 62.29M 19.64M 26.16M 17.23M 13.49M 46.36M 23.65M
divided by
Revenue 71.24M 56.56M 74.59M 62.38M 19.64M 26.29M 17.33M 13.61M 48.26M 26.35M
Gross Margin 100.00% 100.00% 93.91% 99.86% 100.00% 99.50% 99.43% 99.10% 96.07% 89.76%

Low Capital Intensity over the past 10 years

BCRX has consistently used a small portion of their Net Income buying new equipment or investing in new facilities. This indicates that BCRX may require minimal investment to stay competitive. This leaves them with extra money to spend on growing their business and potentially buying back stock.

-% of Profits are being spent on Capital Expenditures, like Property, Plant, & Equipment, required to run the business.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Capital Expenditure - 1.21M 603,692.00 324,764.00 55,000.00 113,000.00 30,000.00 106,000.00 5.12M 5.28M
divided by
Net Income -29.06M -24.73M -13.45M -33.85M -56.95M -39.08M -30.11M -45.19M -43.02M -55.14M
Capital Expenditure Ratio - -4.90% -4.49% -0.96% -0.10% -0.29% -0.10% -0.23% -11.91% -9.57%

No Dividend History over the past 10 years

BCRX has never distributed dividends or has recently suspended their dividend distribution.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Dividend Paid - - - - - - - - - -
divided by
Shares Outstanding 32.77M 38.06M 38.93M 44.56M 45.14M 49.47M 55.22M 66.77M 72.90M 73.70M
Dividend Paid Per Share - - - - - - - - - -
Price at Year End 5.89 1.19 6.44 5.13 2.47 1.40 7.64 12.10 10.49 6.33
Dividend Yield - - - - - - - - - -

No History of Stock Buybacks over the past 10 years

We're neutral on this. It's not necessarily good or bad that BCRX hasn't initiated a stock buyback.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Shares Outstanding 32.77M 38.06M 38.93M 44.56M 45.14M 49.47M 55.22M 66.77M 72.90M 73.70M
Stock Bought Back - -13.90% -2.22% -12.65% -1.28% -8.75% -10.40% -17.31% -8.41% -1.08%
Share your thoughts about BCRX

Sign Up or Log In to start contributing!


Discussion

Nothing here yet. Be the first to post!